http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8783712&dopt=Abstract
|
Clin Infect Dis 1996 Jun;22(6):1069-76 |
Comment in:
·
Clin Infect Dis. 1996 Jun;22(6):1077-8
Invasive disease due to Haemophilus
influenzae serotype f: clinical and epidemiologic characteristics in the H.
influenzae serotype b vaccine era. The Haemophilus influenzae Study Group.
Urwin G, Krohn JA, Deaver-Robinson K, Wenger JD, Farley MM.
Department of Medicine, Veterans Administration Medical Center, Decatur,
Georgia 30033, USA.
With the decline in the rate of infections caused by Haemophilus influenzae
serotype b, H. influenzae serotype f (Hif) is becoming a relatively important
cause of invasive disease due to H. influenzae. We identified 91 cases of
invasive Hif infections in a multistate area over a 6-year period. The
incidence of invasive Hif disease was 0.5 case per 1,000,000 population in 1989
and 1.9 cases per 1,000,000 population in 1994. The proportion of all invasive
H. influenzae disease caused by Hif rose from 1% in 1989 to 17% in 1994.
Seventy-two percent of cases occurred in adults, and 26% of cases occurred in
children younger than 5 years of age. Respiratory tract infections accounted
for 82% of adult cases, and most adults had significant underlying diseases. In
children, pneumonia and meningitis each accounted for 40% of cases,
respectively. Overall mortality was 30% among adults, and 21% among children.
Molecular typing demonstrated limited overall diversity in Hif isolates.
Continued surveillance is warranted to evaluate the trend toward the increasing
incidence of Hif disease that was noted in this study.
PMID: 8783712 [PubMed - indexed for MEDLINE]
ALL
INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR
GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE
KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED
AS PROVIDING MEDICAL OR LEGAL ADVICE. THE DECISION WHETHER OR NOT TO
VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU
ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.